Olaratumab
Olaratumab was approved in 2016 with doxorubicin for soft tissue sarcoma after a small trial suggested it added almost a year of life, but the large confirmatory trial found no benefit and it was withdrawn in 2019, a warning case for accelerated approvals.
Overview
Eli Lilly's olaratumab received FDA accelerated approval in October 2016, and EU conditional approval the same year, for adults with soft tissue sarcoma not curable by surgery or radiotherapy, in combination with doxorubicin, after a randomised phase 2 trial reported median survival of 26.5 months versus 14.7 months with doxorubicin alone. The phase 3 ANNOUNCE trial in 509 patients then showed no difference in overall survival, and Lilly withdrew the drug worldwide in 2019. The episode is cited whenever the reliability of small randomised phase 2 survival signals is debated.
A human IgG1 antibody that binds platelet-derived growth factor receptor alpha and stops its ligands activating it on tumour and stromal cells.
1.Olaratumab binds its target.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2016 | Soft tissue sarcoma not curable by surgery or radiotherapy, with doxorubicin (accelerated approval) · Withdrawn in 2019 after the ANNOUNCE trial |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Olaratumab" OR ABSTRACT:"Olaratumab" OR TITLE:"Lartruvo" OR ABSTRACT:"Lartruvo" OR TITLE:"IMC-3G3" OR ABSTRACT:"IMC-3G3" OR TITLE:"LY3012207" OR ABSTRACT:"LY3012207") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Olaratumab, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentEthiodized oil
Shares Doxorubicin and the tag chembl-universe.
- TreatmentOlmutinib
Shares Small-molecule kinase inhibitors and the tag chembl-universe.
- TreatmentStreptozocin
Shares Doxorubicin and the tag chembl-universe.
- TreatmentPixantrone
Shares Doxorubicin and the tag chembl-universe.
- TreatmentInfigratinib
Shares Small-molecule kinase inhibitors and the tag chembl-universe.
- TreatmentTrilaciclib
Shares Small-molecule kinase inhibitors and the tag chembl-universe.
- TrialA Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
Shares Eli Lilly (incl. Loxo), Sarcomas (soft tissue, bone, GIST).
- TrialANNOUNCE